Published in Cancer Invest on October 01, 2008
Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol (2010) 1.13
Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol (2013) 1.09
HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One (2011) 1.05
Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. Cell Death Dis (2013) 1.01
A Review on the Relationship between SGLT2 Inhibitors and Cancer. Int J Endocrinol (2014) 1.00
Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience (2014) 0.96
The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol (2010) 0.84
Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect. Acta Pharmacol Sin (2016) 0.81
EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma. Am J Cancer Res (2015) 0.79
Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. Am J Transl Res (2013) 0.78
Tumor suppressor gene adenomatous polyposis coli downregulates intestinal transport. Pflugers Arch (2011) 0.78
The association of apoptotic protein expressions sensitive to apoptosis gene, p73 and p53 with the prognosis of cervical carcinoma. Onco Targets Ther (2014) 0.76
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 4.30
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology (2009) 2.92
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging (2004) 2.21
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology (2004) 1.99
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest (2012) 1.84
Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med (2011) 1.80
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Clinical impact of capsule endoscopy on further strategy and long-term clinical outcome in patients with obscure bleeding. Gastrointest Endosc (2008) 1.72
Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One (2012) 1.70
Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol (2004) 1.69
Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg (2005) 1.69
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2002) 1.65
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Pancreatic tuberculosis diagnosed by EUS: one disease, many faces. JOP (2013) 1.62
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol (2010) 1.61
Open intraperitoneal versus retromuscular mesh repair for umbilical hernias less than 3 cm diameter. Am J Surg (2010) 1.60
Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl (2006) 1.57
ABO-mismatch adult living donor liver transplantation using antigen-specific immunoadsorption and quadruple immunosuppression without splenectomy. Liver Transpl (2006) 1.57
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med (2011) 1.55
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology (2002) 1.55
Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging (2012) 1.53
188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med (2005) 1.52
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum (2006) 1.50
Laparoscopic evaluation shows deficiencies in memory ring deployment during small ventral hernia repair. World J Surg (2010) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
A dramatic case of calciphylaxis 20 years after kidney transplantation. Nephrol Dial Transplant (2004) 1.47
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease. Clin Chem Lab Med (2015) 1.41
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum (2003) 1.41
Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis (2009) 1.39
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol (2002) 1.34
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol (2002) 1.32
Use of topical hemostatic agents during liver resection. Dig Surg (2007) 1.31
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant (2005) 1.26
Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One (2010) 1.26
Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? Ann Surg (2003) 1.26
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol (2009) 1.24
Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol (2011) 1.23
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 1.20
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut (2012) 1.19
Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis (2012) 1.18
Transinguinal preperitoneal memory ring patch versus Lichtenstein repair for unilateral inguinal hernias. Langenbecks Arch Surg (2009) 1.18
Re: Plexiform angiomyxoid myofibroblastic tumor of the stomach. Am J Surg Pathol (2008) 1.17
Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery (2010) 1.15
Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res (2009) 1.14
Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med (2006) 1.12
Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol (2007) 1.12
ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.12
FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med (2013) 1.12
The immune system and cancer. Cancer Biother Radiopharm (2009) 1.11
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum (2009) 1.09
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer (2010) 1.09
Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys (2006) 1.07
Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch (2007) 1.06
Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep (2002) 1.06
Hydroxylase inhibition abrogates TNF-alpha-induced intestinal epithelial damage by hypoxia-inducible factor-1-dependent repression of FADD. J Immunol (2010) 1.05
Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood (2002) 1.05
The value of laparoscopic liver surgery for solid benign hepatic tumors. Surg Endosc (2007) 1.03